Find a Trial

Trial Summary

Protocol No.CTO-MT-0169-001
Principal InvestigatorAbonour, Rafat
PhasePhase I
Age GroupAdult
TitleA Phase 1, Open-Label, Dose-Escalation, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TAK-169 in Patients With Relapsed or Refractory Multiple Myeloma
DescriptionThis will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Confirmed diagnosis of MM per the revised IMWG diagnostic criteria
  • Patients with RRMM who have failed treatment with, are intolerant to, or are not candidates for available therapies that are known to confer clinical benefit
For a full list of participation criteria, please visit
Applicable Disease SitesMultiple Myeloma
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632